ENDP:NSD-Endo International plc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 6.93

Change

0.00 (0.00)%

Market Cap

USD 1.60B

Volume

4.05M

Average Target Price

USD 7.00 (+1.01%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Endo International plc manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; TESTOPEL for TRT in conditions associated with a deficiency or absence of endogenous testosterone; AVEED to treat hypogonadism; PERCOCET to treat moderate-to-moderately-severe pain; VOLTAREN gel for the relief of joint pain of osteoarthritis; LIDODERM for the relief of pain; TESTOPEL, an implantable pellet indicated for TRT in conditions; EDEX to treat erectile dysfunction; and LIDODERM a topical patch product containing lidocaine. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays; and products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, and oncology. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. Address: Minerva House, Dublin, Ireland, 4

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-23 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CGC Canopy Growth Corporation

N/A

USD12.70B N/A N/A
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
APHA Aphria Inc

N/A

USD4.12B 43.21 454.68
CRON Cronos Group Inc

N/A

USD3.82B 37.11 N/A
PCRX Pacira BioSciences, Inc

N/A

USD2.95B 23.15 65.69
TLRY Tilray, Inc

N/A

USD2.85B N/A N/A
IRWD Ironwood Pharmaceuticals, Inc

N/A

USD1.66B 14.79 14.06
SUPN Supernus Pharmaceuticals, Inc

N/A

USD1.58B 12.42 7.71
ORGO Organogenesis Holdings Inc

N/A

USD1.35B 456.50 77.95

ETFs Containing ENDP

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.48% 14% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.48% 14% F 9% F
Trailing 12 Months  
Capital Gain 17.06% 70% C- 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.06% 70% C- 55% F
Trailing 5 Years  
Capital Gain -88.02% 6% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -88.02% 6% F 4% F
Average Annual (5 Year Horizon)  
Capital Gain -18.80% 28% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.80% 28% F 8% F
Risk Return Profile  
Volatility (Standard Deviation) 51.82% 33% F 24% F
Risk Adjusted Return -36.28% 39% F 17% F
Market Capitalization 1.60B 90% A- 71% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio 16.28 15% F 25% F
EV/EBITDA 9.94 69% D+ 71% C-
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 7.41% 88% B+ 71% C-
Return on Assets 4.42% 88% B+ 82% B-
Debt to Equity Ratio -964.74% 93% A 99% A+
Technical Ratios  
Short Ratio 5.28 44% F 23% F
Short Percent 13.46% 32% F 15% F
Beta 1.42 44% F 35% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector